Canine transitional cell carcinoma cells (K9TCC) was obtained from Prof. Knapp, Purdue (PU, Indiana, USA), canine osteosarcoma cell (Abrams) were obtained from Prof. Rebhurn, (UCD, California, USA) and canine hemangiosarcoma cells (DAL‐4) were obtained from Kerafast Inc. (Massachusetts, USA). The K9TCC and Abrams cells were grown in Dulbecco's modified eagle's medium (Gibco™) containing 10% fetal bovine serum (FBS) (Gibco™), 100 units/ml of penicillin (Gibco™), 100 μg/ml of streptomycin (Gibco™) and 10 mM of 4‐(2‐hydroxyethyl)‐1‐piperazineethanesulfonic acid buffer (Gibco™) and incubated at 5% CO2 and 37°C. The three cell lines are described as TCC (transitional cell carcinoma, K9TCC), OSA (osteosarcoma, Abrams) and hemangiosarcoma (HSA, DAL‐4) in figures and text.
The DAL‐4 cells were grown in Ham F‐12 (Gibco™) containing 10% FBS (Gibco™), 100 μg/ml of primocin, 0.05 mg/ml of endothelial cell growth supplement, 0.1 mg/ml of heparin (Sigma‐Aldrich®), 10 mM of HEPES buffer (Gibco™) and incubated at 37°C in 5% CO2 humidified incubator. All cell lines were free of mycoplasma.
The DAL‐4 cells were grown in Ham F‐12 (Gibco™) containing 10% FBS (Gibco™), 100 μg/ml of primocin, 0.05 mg/ml of endothelial cell growth supplement, 0.1 mg/ml of heparin (Sigma‐Aldrich®), 10 mM of HEPES buffer (Gibco™) and incubated at 37°C in 5% CO2 humidified incubator. All cell lines were free of mycoplasma.